title: An efficacy-dependent effect of cardiac overexpression of beta2-adrenoceptor on ligand affinity in transgenic mice.
abstract: In previous studies, it was shown that the overexpression of beta2-adrenoceptor (beta2AR) in the hearts of transgenic mice (Tg) leads to agonist-independent activation of adenylate cyclase and enhanced myocardial function. Here, we measured the physical coupling of beta2AR and Gs by evaluating the coimmunoprecipitation of beta2AR and Gs and the ligand binding properties of beta2AR in the hearts of Tg mice to investigate the details of the interaction among ligand, receptor, and G protein. The following results were obtained: (i) coimmunoprecipitation of beta2AR and Gs was increased in the absence of agonist in Tg mice compared with the control animals. This demonstrates directly the increased interaction between unliganded beta2AR and Gs, which is consistent with increased background cAMP production and cardiac function in the hearts of Tg mice. (ii) Guanosine-5'-(beta,gamma-imido)triphosphate abolished the association of beta2AR/Gs in the immunoprecipitate. (iii) The affinities for ligands that show agonist (isoproterenol, clenbuterol, and dobutamine), neutral antagonist (alprenolol and timolol), and negative antagonist (propranolol and ICI 118551) activities in this experimental system were increased, not changed and decreased, respectively, in Tg mice compared with the controls. (iv) This efficacy-dependent alteration in ligand affinities was still observed in the presence of a guanosine-5'-(beta,gamma-imido)triphosphate concentration that abolishes beta2AR/Gs coupling. This suggests that the altered beta2AR binding affinities in Tg mice are not due to the increased interaction between beta2AR and Gs. These data cannot be explained by using ternary, quinternary, two-state extended ternary, or cubic ternary complex models. We therefore discuss the results using a "two-state polymerization model" that includes an isomerization step for the conversion of receptor between an inactive and an active form (denoted as R and R*, respectively) and a polymerization of the active state (R*n). The simplest form of this model (i.e., noncooperative dimerization of the receptor) is found to be consistent with the experimental data.
authors.affiliation: Department of Pharmacology and Clinical Pharmacology, Medical Faculty of Ankara University, Turkey. gurdal@bilkent.edu.tr
authors.forename: H
authors.initials: H
authors.lastname: Gürdal
authors.forename: R A
authors.initials: RA
authors.lastname: Bond
authors.forename: M D
authors.initials: MD
authors.lastname: Johnson
authors.forename: E
authors.initials: E
authors.lastname: Friedman
authors.forename: H O
authors.initials: HO
authors.lastname: Onaran
mesh_terms: D000318:Adrenergic beta-Agonists / Q000378:metabolism; D000319:Adrenergic beta-Antagonists / Q000378:metabolism; D000818:Animals; D001667:Binding, Competitive; D002462:Cell Membrane / Q000378:metabolism; D008024:Ligands; D051379:Mice; D008822:Mice, Transgenic; D009206:Myocardium / Q000378:metabolism*; D011108:Polymers; D011233:Precipitin Tests; D011940:Receptor Aggregation; D018343:Receptors, Adrenergic, beta-2 / Q000502:physiology*
chemical_list: D000318:Adrenergic beta-Agonists; D000319:Adrenergic beta-Antagonists; D008024:Ligands; D011108:Polymers; D018343:Receptors, Adrenergic, beta-2